Figure 2

Efficacy through 48 weeks in the overall population. (a) Proportions of viral load responders (<50 copies/ml: FDA snapshot analysis) through 48 weeks (N =313); (b) Median (range) change in CD4⁺ cell count (cells/mm³) from baseline through 48 weeks (missing = excluded).